Drug Profile
LRX 712
Alternative Names: LRX712Latest Information Update: 10 Nov 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 28 Sep 2022 LRX 712 is still in phase II trials for knee osteoarthritis in Netherlands and Austria
- 14 Apr 2021 Novartis re-initiates enrollment in a phase II trial in Osteoarthritis in Netherlands (Intra-articular) (EudraCT2019-002963-92) (NCT04097379)
- 26 Mar 2021 Novartis temporary suspends a phase II trial in Osteoarthritis in Netherlands, to review risk assessment (Intra-articular) (EudraCT2019-002963-92) (NCT04097379)